A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03936777 |
|
Recruitment Status :
Enrolling by invitation
First Posted : May 3, 2019
Last Update Posted : September 17, 2020
|
Sponsor:
Zogenix, Inc.
Collaborator:
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Information provided by (Responsible Party):
Zogenix, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dravet Syndrome Lennox Gastaut Syndrome Epileptic Encephalopathy | Drug: ZX008 (Fenfluramine Hydrochloride) | Phase 3 |
This is an international, multicenter, open-label, long-term safety study of ZX008 in patients with epileptic encephalopathy, including Dravet syndrome or Lennox-Gastaut syndrome. Subjects eligible for participation are those with Dravet syndrome who are currently enrolled in Study ZX008-1503, or those with Lennox-Gastaut syndrome who have successfully completed Study ZX008-1601-Part 2, and are candidates for continued treatment with ZX008 for an extended period of time, or those with Dravet syndrome, Lennox-Gastaut syndrome, or another epileptic encephalopathy who have completed participation in another Zogenix-sponsored study and have been invited to participate in this study.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 650 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Single Group Assisgnment |
| Masking: | None (Open Label) |
| Masking Description: | None (open label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome |
| Actual Study Start Date : | April 22, 2019 |
| Estimated Primary Completion Date : | April 2023 |
| Estimated Study Completion Date : | April 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Lennox-Gastaut syndrome
Pyridoxal 5'-phosphate-dependent epilepsy
CDKL5 deficiency disorder
Genetic epilepsy with febrile seizures plus
MedlinePlus related topics:
Epilepsy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ZX008 (Fenfluramine Hydrochloride)
ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
|
Drug: ZX008 (Fenfluramine Hydrochloride)
Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL. |
Primary Outcome Measures :
- Change in Adverse Events and Serious Adverse Events leading to study withdrawal in subjects receiving open label ZX008 [ Time Frame: Up to 36 months open-label ]Evaluate the long term safety and tolerability of oral dose administration of ZX008
- Changes in laboratory test results [ Time Frame: Up to 36 months open-label ]The analysis will include abnormal hematology and chemistry laboratory results outside of reference ranges
- Changes in heart rate [ Time Frame: Up to 36 months open-label ]The analysis will include change in heart rate using standard measure
- Changes in respiratory rate [ Time Frame: Up to 36 months open-label ]The analysis will include change in resting respiratory rate using standard measure
- Changes in blood pressure [ Time Frame: Up to 36 months open-label ]The analysis will include change in resting blood pressure using standard measure
- Change in body weight [ Time Frame: Up to 36 months open-label ]The analysis will include change in body weight and height by report of BMI in kg/m^2
- Changes in heart rhythm [ Time Frame: Up to 36 months open-label ]The analysis will include changes in heart beat as measured with 12-lead electrocardiogram
- Changes in heart valve function [ Time Frame: Up to 36 months open-label ]The analysis will include change in heart valves as measured with standard echocardiogram
Secondary Outcome Measures :
- Change in convulsive seizure response [ Time Frame: Up to 36 months open-label ]The analysis will include percent improvement per investigator rating
- Change in Cognitive CGI by Parent/Caregiver [ Time Frame: Up to 36 months open-label ]The rating by parent/caregiver of the patient's change in cognitive symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
- Change in Behavioral CGI by Parent/Caregiver [ Time Frame: Up to 36 months open-label ]The rating by parent/caregiver of the patient's change in behavioral symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
- Change in Motor CGI by Parent/Caregiver [ Time Frame: Up to 36 months open-label ]The rating by parent/caregiver of the patient's change in motor symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
- Change in Cognitive CGI by Investigator [ Time Frame: Up to 36 months open-label ]The rating by investigator of the patient's change in cognitive symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
- Change in Behavioral CGI by Investigator [ Time Frame: Up to 36 months open-label ]The rating by investigator of the patient's change in behavioral symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
- Change in Motor CGI by Investigator [ Time Frame: Up to 36 months open-label ]The rating by investigator of the patient's change in motor symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
- Change in Clinical Global Impression by Parent/Caregiver [ Time Frame: Up to 36 months open-label ]The rating by parent/caregiver of the patient's overall change in symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse"
- Change in Clinical Global Impression by Investigator [ Time Frame: Up to 36 months open-label ]The rating by investigator of the patient's overall change in symptoms since the beginning of study as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse"
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or nonpregnant, nonlactating female
- Satisfactory completion of a core study
- Has a rare seizure disorder, such as epileptic encephalopathy and has successfully completed another Zogenix-sponsored clinical trials with ZX008
- Subject's caregiver is willing and able to be compliant with study procedures, visit schedule and study drug accountability
Exclusion Criteria:
- Current cardiac valvulopathy or pulmonary hypertension that is clinically significant
- Moderate or severe hepatic impairment
- Receiving monoamine oxidase inhibitors, serotonin agonists, serotonin antagonists, and serotonin reuptake inhibitors within 14 days of receiving ZX008
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03936777
Locations
Show 28 study locations
Sponsors and Collaborators
Zogenix, Inc.
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
| Responsible Party: | Zogenix, Inc. |
| ClinicalTrials.gov Identifier: | NCT03936777 |
| Other Study ID Numbers: |
ZX008-1900 |
| First Posted: | May 3, 2019 Key Record Dates |
| Last Update Posted: | September 17, 2020 |
| Last Verified: | September 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Brain Diseases Epilepsy Epilepsies, Myoclonic Lennox Gastaut Syndrome Syndrome Disease Pathologic Processes Central Nervous System Diseases Nervous System Diseases Epilepsy, Generalized |
Epileptic Syndromes Genetic Diseases, Inborn Fenfluramine Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs |